Breaking News Instant updates and real-time market news.

MYL

Mylan

$41.65

-0.2 (-0.48%)

08:44
06/14/18
06/14
08:44
06/14/18
08:44

Technical Take: Mylan falls after FDA says generic Advair has minor deficiencies

The stock was last down over 2.9% to $40.44 in pre-market trading. At that price next support is at $39.66. Resistance is at the $41 area.

  • 13

    Nov

MYL Mylan
$41.65

-0.2 (-0.48%)

06/14/18
MSCO
06/14/18
NO CHANGE
MSCO
Underweight
Morgan Stanley says Mylan Advair news likely seen as positive for Innoviva
After Mylan (MYL) announced the FDA has identified minor deficiencies that will delay the launch of its generic Advair product, Morgan Stanley analyst Matthew Harrison said he expects the market to view this as a positive for Innoviva (INVA), which he predicts will be up 5% or more on the news. Harrison, who continues to anticipate a generic Advair entry in 2018, keeps an Underweight rating on Innoviva shares.
06/14/18
WELS
06/14/18
NO CHANGE
WELS
Market Perform
Advair generic delay negative news for Mylan, says Wells Fargo
Wells Fargo analyst David Maris notes that Mylan announced that it received an update from the FDA concerning its generic Advair application and the FDA has identified minor deficiencies that will be relayed in a Complete Response Letter on June 27. While noting that he does not know how long it will take Mylan to respond to the CRL, the analyst says the delay is negative news for the company, but less so from a financial basis than a sentiment basis. Further, Maris believes this delay is important as this is a high-profile product that may already be in market expectations, and the delay may take away some excitement about a near-term catalyst. The fact Mylan said it will determine after getting the CRL whether this has any impact to its 2018 outlook, also creates some uncertainty, he contends. Maris reiterates a Market Perform rating on the shares.
06/14/18
MSCO
06/14/18
NO CHANGE
Target $50
MSCO
Overweight
Morgan Stanley says generic Advair delay a small negative for Mylan
Morgan Stanley analyst David Risinger called Mylan's announcement that generic Advair will not be approved by its June 27 action date a "small negative, but not a major surprise." He sees potential for approval this fall, while noting that the company previously warned with its Q1 earnings release that there was risk that it could need to lower its 2018 guidance range. He keeps an Overweight rating on Mylan shares, citing the stock's low valuation and the company's pipeline opportunities.
06/14/18
RBCM
06/14/18
NO CHANGE
Target $42
RBCM
Sector Perform
Mylan's stock may pull back through Q2, says RBC Capital
RBC Capital analyst Randall Stanicky kept his $42 price target and Sector Perform rating on Mylan following yesterday's FDA delay of generic Advair due to "minor deficiencies". The analyst notes that the company may be faced with worse than expressed business pressure and is also concerned that the Street may have over-modeled the Advair contribution, warning that the stock price may pull back through Q2. Stanicky says investors should await a better entry point opportunity on Mylan.

TODAY'S FREE FLY STORIES

NKE

Nike

$73.94

-0.785 (-1.05%)

07:37
06/22/18
06/22
07:37
06/22/18
07:37
Downgrade
Nike rating change  »

Nike downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

AYX

Alteryx

$38.63

-1.21 (-3.04%)

07:36
06/22/18
06/22
07:36
06/22/18
07:36
Initiation
Alteryx initiated  »

Alteryx initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALBO

Albireo Pharma

$36.05

1.05 (3.00%)

07:36
06/22/18
06/22
07:36
06/22/18
07:36
Conference/Events
Albireo Pharma management to meet with Needham »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

INTC

Intel

$52.19

-1.27 (-2.38%)

, JPM

JPMorgan

$107.52

-0.04 (-0.04%)

07:35
06/22/18
06/22
07:35
06/22/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

INTC

Intel

$52.19

-1.27 (-2.38%)

JPM

JPMorgan

$107.52

-0.04 (-0.04%)

MS

Morgan Stanley

$49.78

-0.095 (-0.19%)

PG

Procter & Gamble

$76.44

0.59 (0.78%)

LUV

Southwest

$53.15

1.16 (2.23%)

PAGS

PagSeguro Digital

$29.42

0.91 (3.19%)

COTY

Coty

$14.48

0.03 (0.21%)

HBI

Hanesbrands

$22.04

0.615 (2.87%)

SYK

Stryker

$169.81

0.21 (0.12%)

ECA

Encana

$12.19

-0.235 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

  • 24

    Jul

  • 26

    Jul

  • 12

    Oct

  • 22

    Jun

SRPT

Sarepta

$149.57

-4.12 (-2.68%)

07:34
06/22/18
06/22
07:34
06/22/18
07:34
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBIO

iBio

$0.95

-0.12 (-11.22%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Syndicate
iBio raises $16M in a public offering »

The securities offered by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$462.87

-2.66 (-0.57%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Periodicals
Chipotle will test new menu items, strategy, NY Times reports »

Chipotle is adding five…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 26

    Jul

ABBV

AbbVie

$95.55

-2.72 (-2.77%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Recommendations
AbbVie analyst commentary  »

AbbVie most exposed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEA

Lear

$198.83

-2.565 (-1.27%)

07:32
06/22/18
06/22
07:32
06/22/18
07:32
Conference/Events
Lear to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

, NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

07:31
06/22/18
06/22
07:31
06/22/18
07:31
Hot Stocks
Qualcomm extends cash offer for NXP Semiconductors to June 29 »

Qualcomm (QCOM) announced…

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

, RIG

Transocean

$11.94

-0.575 (-4.60%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

RIG

Transocean

$11.94

-0.575 (-4.60%)

CSX

CSX

$64.06

-0.81 (-1.25%)

Z

Zillow

$61.83

-2.84 (-4.39%)

KMB

Kimberly-Clark

$100.15

-1.51 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Hot Stocks
Breaking Hot Stocks news story on Williams Scotsman »

WillScot Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SENS

Senseonics

$4.96

0.1 (2.06%)

07:29
06/22/18
06/22
07:29
06/22/18
07:29
Recommendations
Senseonics analyst commentary  »

Senseonics FDA approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

CAKE

Cheesecake Factory

$59.87

2.13 (3.69%)

07:28
06/22/18
06/22
07:28
06/22/18
07:28
Downgrade
Cheesecake Factory rating change  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Conference/Events
Williams Scotsman to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SLNO

Soleno Therapeutics

$2.34

-0.02 (-0.85%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Initiation
Soleno Therapeutics initiated  »

Soleno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$91.53

-1.84 (-1.97%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Recommendations
Trade Desk analyst commentary  »

Trade Desk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTX

Heron Therapeutics

$40.00

9.3 (30.29%)

07:25
06/22/18
06/22
07:25
06/22/18
07:25
Recommendations
Heron Therapeutics analyst commentary  »

Heron Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

KLAC

KLA-Tencor

$110.31

0.54 (0.49%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Downgrade
KLA-Tencor rating change  »

KLA-Tencor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$165.62

-3.64 (-2.15%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Red Hat analyst commentary  »

Red Hat price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

CSCO

Cisco

$43.17

-0.58 (-1.33%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Cisco analyst commentary  »

Cisco selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 12

    Jul

TNDM

TNDM

, DXCM

DexCom

$99.72

-0.88 (-0.87%)

07:23
06/22/18
06/22
07:23
06/22/18
07:23
Recommendations
TNDM, DexCom analyst commentary  »

Tandem Diabetes'…

TNDM

TNDM

DXCM

DexCom

$99.72

-0.88 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

DRI

Darden

$107.07

13.8 (14.80%)

07:22
06/22/18
06/22
07:22
06/22/18
07:22
Recommendations
Darden analyst commentary  »

Darden price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

VSLR

Vivint Solar

$5.00

-0.05 (-0.99%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Upgrade
Vivint Solar rating change  »

Vivint Solar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ES

Eversource

$55.70

-0.1 (-0.18%)

, CTWS

Connecticut Water

$66.53

0.28 (0.42%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Upgrade
Eversource, Connecticut Water rating change  »

Eversource upgraded to…

ES

Eversource

$55.70

-0.1 (-0.18%)

CTWS

Connecticut Water

$66.53

0.28 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.